Related Experiment Video

Updated: Apr 25, 2026

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
10:13

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

Published on: August 12, 2014

13.1K

Effect of tanshinone IIA in an in vitro model of Graves' orbitopathy

Soolienah Rhiu1, Min Kyung Chae2, Eun Jig Lee3

  • 1Department of Ophthalmology, Institute of Vision Research, Yonsei University College of Medicine, Seoul, Korea Department of Ophthalmology, Hallym University College of Medicine, Dongtan Sacred Heart Hospital, Hwaseong, Korea.

Investigative Ophthalmology & Visual Science
|August 28, 2014
PubMed
Abstract

Insights

Tanshinone IIA (TanIIA) from Salvia miltiorrhiza demonstrates potent anti-inflammatory, antioxidant, and antiadipogenic properties in Graves' orbitopathy (GO) orbital fibroblasts. These findings support TanIIA

Area of Science:

  • Endocrinology and Metabolism
  • Immunology
  • Pharmacology

Background:

  • Graves' orbitopathy (GO) is an autoimmune condition affecting orbital tissues.
  • Orbital fibroblasts play a key role in the pathogenesis of GO, contributing to inflammation and adipogenesis.
  • Current treatments for GO have limitations, highlighting the need for novel therapeutic agents.

Purpose of the Study:

  • To investigate the therapeutic potential of tanshinone IIA (TanIIA), a compound from Salvia miltiorrhiza, in primary cultures of orbital fibroblasts from GO patients.
  • To evaluate the anti-inflammatory, antioxidant, and antiadipogenic effects of TanIIA in this cellular model.

Main Methods:

  • Primary orbital fibroblasts from GO patients were treated with varying concentrations of TanIIA.
  • Real-time PCR was used to assess the expression of proinflammatory cytokines (IL-6, IL-8, MCP-1).
  • Intracellular reactive oxygen species (ROS) generation and heme oxygenase-1 (HO-1) expression were measured to evaluate antioxidant activity.
  • Adipogenesis was assessed by Oil Red O staining and Western blot analysis of adipogenesis-related factors (PPARγ, C/EBPα, C/EBPβ).

Main Results:

  • TanIIA significantly inhibited the expression of IL-6, IL-8, and MCP-1 mRNA in a dose-dependent manner.
  • TanIIA reduced ROS generation and upregulated HO-1 expression, indicating antioxidant effects.
  • TanIIA treatment inhibited adipogenesis in a dose-dependent manner, evidenced by reduced Oil Red O staining and decreased expression of PPARγ and C/EBPα.

Conclusions:

  • Tanshinone IIA exhibits significant anti-inflammatory, antioxidant, and antiadipogenic activities in primary orbital fibroblasts.
  • These findings suggest that TanIIA may hold therapeutic promise for treating Graves' orbitopathy.
  • Further research is warranted to explore the clinical application of TanIIA in GO management.
Keywords:
Graves' orbitopathyadipogenesisheme oxygenase-1inflammationorbital fibroblastsoxidative stresstanshinone IIA

More Related Videos

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

12.6K
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.7K

Related Concept Videos

Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor,...
15
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence...
15
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH...
18